Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.25
DYAX's Cash to Debt is ranked higher than
62% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. DYAX: 2.25 )
DYAX' s 10-Year Cash to Debt Range
Min: 0.37   Max: 32.79
Current: 2.25

0.37
32.79
Equity to Asset 0.49
DYAX's Equity to Asset is ranked higher than
63% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DYAX: 0.49 )
DYAX' s 10-Year Equity to Asset Range
Min: -0.93   Max: 0.76
Current: 0.49

-0.93
0.76
F-Score: 4
Z-Score: 9.01
M-Score: -1.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1.51
DYAX's Operating margin (%) is ranked higher than
83% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. DYAX: -1.51 )
DYAX' s 10-Year Operating margin (%) Range
Min: -389.57   Max: -1.51
Current: -1.51

-389.57
-1.51
Net-margin (%) -14.53
DYAX's Net-margin (%) is ranked higher than
80% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. DYAX: -14.53 )
DYAX' s 10-Year Net-margin (%) Range
Min: -393.89   Max: -14.53
Current: -14.53

-393.89
-14.53
ROE (%) -13.39
DYAX's ROE (%) is ranked higher than
80% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. DYAX: -13.39 )
DYAX' s 10-Year ROE (%) Range
Min: -1406.43   Max: -17.98
Current: -13.39

-1406.43
-17.98
ROA (%) -6.06
DYAX's ROA (%) is ranked higher than
83% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. DYAX: -6.06 )
DYAX' s 10-Year ROA (%) Range
Min: -89.25   Max: -6.76
Current: -6.06

-89.25
-6.76
ROC (Joel Greenblatt) (%) -24.05
DYAX's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. DYAX: -24.05 )
DYAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1121.26   Max: -21.55
Current: -24.05

-1121.26
-21.55
Revenue Growth (3Y)(%) 7.60
DYAX's Revenue Growth (3Y)(%) is ranked higher than
75% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. DYAX: 7.60 )
DYAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -37.4   Max: 21.1
Current: 7.6

-37.4
21.1
EBITDA Growth (3Y)(%) -100.00
DYAX's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. DYAX: -100.00 )
DYAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -100   Max: 10.4
Current: -100

-100
10.4
EPS Growth (3Y)(%) -36.40
DYAX's EPS Growth (3Y)(%) is ranked lower than
115% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. DYAX: -36.40 )
DYAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -37.4   Max: 11.9
Current: -36.4

-37.4
11.9
» DYAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

DYAX Guru Trades in Q1 2014

Steven Cohen 960,155 sh (New)
Louis Moore Bacon 75,000 sh (New)
Jim Simons 742,804 sh (+40.68%)
PRIMECAP Management 11,806,990 sh (unchged)
Chuck Royce 485,600 sh (-39.98%)
Paul Tudor Jones 16,099 sh (-70.38%)
» More
Q2 2014

DYAX Guru Trades in Q2 2014

Joel Greenblatt 46,505 sh (New)
Steven Cohen 44,100 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 11,129,830 sh (-5.74%)
Chuck Royce 380,200 sh (-21.71%)
Jim Simons 469,186 sh (-36.84%)
» More
Q3 2014

DYAX Guru Trades in Q3 2014

Paul Tudor Jones 17,323 sh (New)
Steven Cohen 56,500 sh (+28.12%)
Jim Simons Sold Out
PRIMECAP Management 10,884,960 sh (-2.2%)
Joel Greenblatt 44,152 sh (-5.06%)
Chuck Royce 244,900 sh (-35.59%)
» More
Q4 2014

DYAX Guru Trades in Q4 2014

Paul Tudor Jones 25,023 sh (+44.45%)
Joel Greenblatt 52,618 sh (+19.17%)
Steven Cohen Sold Out
PRIMECAP Management 10,869,860 sh (-0.14%)
Chuck Royce 179,600 sh (-26.66%)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.01%$6.11 - $9.96 $ 15.67106%46505
PRIMECAP Management 2013-06-30 Add 24.89%0.01%$2.29 - $4.42 $ 15.67381%10906810
PRIMECAP Management 2012-09-30 New Buy0.04%$2.13 - $2.75 $ 15.67532%8732900
PRIMECAP Management 2012-06-30 Sold Out 0.02%$1.48 - $2.19 $ 15.67801%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 20.10
DYAX's P/B is ranked higher than
60% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. DYAX: 20.10 )
DYAX' s 10-Year P/B Range
Min: 2.05   Max: 74.67
Current: 20.1

2.05
74.67
P/S 26.20
DYAX's P/S is ranked higher than
75% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. DYAX: 26.20 )
DYAX' s 10-Year P/S Range
Min: 2.46   Max: 26.58
Current: 26.2

2.46
26.58
EV-to-EBIT -1591.32
DYAX's EV-to-EBIT is ranked higher than
71% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DYAX: -1591.32 )
DYAX' s 10-Year EV-to-EBIT Range
Min: -2193.6   Max: -2
Current: -1591.32

-2193.6
-2
Current Ratio 9.52
DYAX's Current Ratio is ranked higher than
86% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. DYAX: 9.52 )
DYAX' s 10-Year Current Ratio Range
Min: 1.72   Max: 9.52
Current: 9.52

1.72
9.52
Quick Ratio 9.31
DYAX's Quick Ratio is ranked higher than
86% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. DYAX: 9.31 )
DYAX' s 10-Year Quick Ratio Range
Min: 1.72   Max: 9.31
Current: 9.31

1.72
9.31
Days Inventory 192.72
DYAX's Days Inventory is ranked higher than
78% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DYAX: 192.72 )
DYAX' s 10-Year Days Inventory Range
Min: 124.07   Max: 821.79
Current: 192.72

124.07
821.79
Days Sales Outstanding 54.58
DYAX's Days Sales Outstanding is ranked higher than
84% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. DYAX: 54.58 )
DYAX' s 10-Year Days Sales Outstanding Range
Min: 37.74   Max: 101.42
Current: 54.58

37.74
101.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 29.00
DYAX's Price/Net Cash is ranked higher than
77% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. DYAX: 29.00 )
DYAX' s 10-Year Price/Net Cash Range
Min: 7.57   Max: 251.17
Current: 29

7.57
251.17
Price/Net Current Asset Value 25.30
DYAX's Price/Net Current Asset Value is ranked higher than
76% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. DYAX: 25.30 )
DYAX' s 10-Year Price/Net Current Asset Value Range
Min: 6.61   Max: 94.19
Current: 25.3

6.61
94.19
Price/Tangible Book 20.10
DYAX's Price/Tangible Book is ranked higher than
65% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. DYAX: 20.10 )
DYAX' s 10-Year Price/Tangible Book Range
Min: 1.05   Max: 72
Current: 20.1

1.05
72
Price/Median PS Value 3.20
DYAX's Price/Median PS Value is ranked higher than
71% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. DYAX: 3.20 )
DYAX' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 2.84
Current: 3.2

0.15
2.84
Earnings Yield (Greenblatt) -0.10
DYAX's Earnings Yield (Greenblatt) is ranked lower than
65% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. DYAX: -0.10 )
DYAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.1   Max: 0
Current: -0.1

-0.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DY8.Germany,
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for DYAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: DYAX, IBI, FARM, TAP, DBM Mar 19 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. Reports Operating Results (10-K) Mar 02 2011 
Dyax Corp. Reports Operating Results (10-Q) Nov 02 2010 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares Sep 15 2010 
Dyax Corp. (DYAX) CFO George V Migausky buys 12,000 Shares Aug 25 2010 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Weekly CFO Buy Highlights: F.N.B. Corp, Great Wolf Resorts Inc, Dyax Corp, Transcat Inc, Cal Dive In Jun 20 2009 
Dyax Corp. (DYAX) CFO George V Migausky buys 9,000 Shares Jun 16 2009 

More From Other Websites
10-K for Dyax Corp. Mar 01 2015
DYAX CORP Files SEC form 10-K, Annual Report Feb 27 2015
Dyax reports 4Q loss Feb 24 2015
Dyax reports 4Q loss Feb 24 2015
Dyax Corp. Announces Fourth Quarter and Full Year 2014 Financial Results Feb 24 2015
DYAX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 24 2015
Q4 2014 Dyax Corp Earnings Release - Time Not Supplied Feb 24 2015
Dyax Corp. Announces Fourth Quarter and Full Year 2014 Financial Results Feb 24 2015
Dyax Corp. to Participate in Upcoming Investor Conferences Feb 18 2015
Dyax Corp. to Participate in Upcoming Investor Conferences Feb 18 2015
Dyax aims at preventative treatment for rare swelling disease Feb 12 2015
Dyax Corp. to Host Fourth Quarter and Year End 2014 Earnings Call and Webcast Feb 10 2015
Dyax Corp. to Participate in the Leerink Partners 2015 Global Healthcare Conference Feb 04 2015
Dyax Corp. to Participate in the Leerink Partners 2015 Global Healthcare Conference Feb 04 2015
Looking for a Growth Stock? Why It is Time to Focus on Dyax Corp. (DYAX) - Tale of the Tape Jan 30 2015
Will Dyax Corp. (DYAX) Continue to Surge Higher? - Tale of the Tape Jan 27 2015
VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Directors Jan 20 2015
DYAX CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 12 2015
Can Dyax (DYAX) Keep the Earnings Streak Alive This Quarter? Dec 10 2014
Dyax Corp. to Participate in the 25th Annual Oppenheimer Healthcare Conference Dec 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK